Henrik Horndalsveen
- PhD student; MD
- +47 22 78 13 83
Publications 2024
Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma
Front Immunol, 15, 1480183
DOI 10.3389/fimmu.2024.1480183, PubMed 39687621
Thoracic radiation in combination with erlotinib-results from a phase 2 randomized trial
Front Oncol, 14, 1412716
DOI 10.3389/fonc.2024.1412716, PubMed 39148905
Publications 2023
Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC
Front Oncol, 13, 1217424
DOI 10.3389/fonc.2023.1217424, PubMed 37476372
Publications 2022
[Checkpoint inhibitor-induced myocarditis]
Tidsskr Nor Laegeforen, 142 (18)
DOI 10.4045/tidsskr.21.0817, PubMed 36511752
Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial
Mol Oncol, 17 (3), 487-498
DOI 10.1002/1878-0261.13330, PubMed 36330681
Publications 2021
NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
J Transl Med, 19 (1), 232
DOI 10.1186/s12967-021-02905-3, PubMed 34059094
Publications 2017
[Cancer patient in his 50's with troublesome palpitations]
Tidsskr Nor Laegeforen, 137 (16)
DOI 10.4045/tidsskr.17.0204, PubMed 28871750
Cancer patient in the 50s with troublesome palpitations
Tidsskr. Nor. Laegeforen., 137 (16), 1210-1213